TABLE 3.

Median, quartile 1 (Q1) and quartile 3 (Q3) duration of exposure (days prescribed +30 days) by treatment exposure group for each included outcome

Outcome	Treatment exposure	Median	Q1	Q3
Arrhythmia	Inhaled corticosteroids	60	60	123
	Macrolide monotherapy	95	60	201
Myocardial infarction	Inhaled corticosteroids	73	60	143
	Macrolide monotherapy	109	60	228
Hip fracture	Inhaled corticosteroids	72	60	143
	Macrolide monotherapy	109	60	228
Opportunistic infection	Inhaled corticosteroids	69	60	142
	Macrolide monotherapy	107	60	220
Sensorineural hearing loss	Inhaled corticosteroids	63	60	138
	Macrolide monotherapy	101	60	208